{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:17:50Z","timestamp":1783498670523,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05053-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:59:14Z","timestamp":1778155154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revealing the promising therapeutic targets and prognostic markers of primary mediastinal large B-cell lymphoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yuge","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"12","key":"5053_CR1","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871\u20139.","journal-title":"Blood"},{"issue":"4","key":"5053_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/10428194.2023.2297939","volume":"65","author":"AD Attygalle","year":"2024","unstructured":"Attygalle AD, et al. The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update. Leuk Lymphoma. 2024;65(4):413\u201329.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5053_CR3","doi-asserted-by":"publisher","first-page":"e865","DOI":"10.1016\/j.clml.2021.06.012","volume":"21","author":"Z Ahmed","year":"2021","unstructured":"Ahmed Z, et al. Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. Clin Lymphoma Myeloma Leuk. 2021;21(11):e865\u201375.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5053_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ. Primary mediastinal large B-cell lymphoma. Blood. 2022;140(9):955\u201370.","journal-title":"Blood"},{"key":"5053_CR5","doi-asserted-by":"publisher","first-page":"654854","DOI":"10.3389\/fonc.2021.654854","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, et al. Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions. Front Oncol. 2021;11:654854.","journal-title":"Front Oncol"},{"issue":"27","key":"5053_CR6","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"16","key":"5053_CR7","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","volume":"129","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328\u201330.","journal-title":"Blood"},{"issue":"9","key":"5053_CR8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen ED, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394\u2013402.","journal-title":"Blood"},{"issue":"9","key":"5053_CR9","first-page":"3019","volume":"109","author":"L Renaud","year":"2024","unstructured":"Renaud L, et al. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed\/refractory primary mediastinal large B-cell lymphoma. Haematologica. 2024;109(9):3019\u201323.","journal-title":"Haematologica"},{"issue":"33","key":"5053_CR10","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.19.01492","volume":"37","author":"PL Zinzani","year":"2019","unstructured":"Zinzani PL, et al. Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019;37(33):3081\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5053_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"10254","key":"5053_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"5","key":"5053_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","volume":"38","author":"A Chiappella","year":"2024","unstructured":"Chiappella A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024;38(5):1107\u201314.","journal-title":"Leukemia"},{"issue":"12","key":"5053_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, et al. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22(12):976\u201395.","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"5053_CR15","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood"},{"issue":"6","key":"5053_CR16","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1182\/blood-2004-09-3701","volume":"105","author":"I Melzner","year":"2005","unstructured":"Melzner I, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535\u201342.","journal-title":"Blood"},{"issue":"4","key":"5053_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ng.2900","volume":"46","author":"J Gunawardana","year":"2014","unstructured":"Gunawardana J, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4):329\u201335.","journal-title":"Nat Genet"},{"issue":"10","key":"5053_CR18","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1182\/blood-2008-03-148726","volume":"112","author":"X Lu","year":"2008","unstructured":"Lu X, et al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood. 2008;112(10):4098\u2013108.","journal-title":"Blood"},{"issue":"18","key":"5053_CR19","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","volume":"131","author":"E Vigan\u00f2","year":"2018","unstructured":"Vigan\u00f2 E, et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood. 2018;131(18):2036\u201346.","journal-title":"Blood"},{"issue":"6","key":"5053_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","volume":"114","author":"O Ritz","year":"2009","unstructured":"Ritz O, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236\u201342.","journal-title":"Blood"},{"issue":"7","key":"5053_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.18632\/oncotarget.1149","volume":"4","author":"O Ritz","year":"2013","unstructured":"Ritz O, et al. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget. 2013;4(7):1093\u2013102.","journal-title":"Oncotarget"},{"key":"5053_CR22","doi-asserted-by":"crossref","unstructured":"Jones D et al. Differential JAK-STAT pathway activation in primary mediastinal large B-cell lymphoma: Two subgroups with differential cytokine activation patterns and predicted responses to kinase inhibitors. Blood. 2009;114(22).","DOI":"10.1182\/blood.V114.22.968.968"},{"issue":"26","key":"5053_CR23","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood.2019002067","volume":"134","author":"B Chapuy","year":"2019","unstructured":"Chapuy B, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134(26):2369\u201382.","journal-title":"Blood"},{"issue":"10","key":"5053_CR24","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","volume":"20","author":"Y Hao","year":"2014","unstructured":"Hao Y, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014;20(10):2674\u201383.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5053_CR25","doi-asserted-by":"publisher","first-page":"9776","DOI":"10.18632\/oncotarget.24267","volume":"9","author":"S Lee","year":"2018","unstructured":"Lee S, et al. Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget. 2018;9(11):9776\u201388.","journal-title":"Oncotarget"},{"issue":"1","key":"5053_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1186\/s12885-019-6303-z","volume":"19","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, et al. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer. 2019;19(1):1080.","journal-title":"BMC Cancer"},{"issue":"33","key":"5053_CR27","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30(33):4161\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5053_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.18632\/oncoscience.35","volume":"1","author":"MT H\u00e4berle","year":"2014","unstructured":"H\u00e4berle MT, et al. Knock-down of BCL6 \/ STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents. Oncoscience. 2014;1(4):283\u20136.","journal-title":"Oncoscience"},{"issue":"4","key":"5053_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/gcc.20420","volume":"46","author":"MA Weniger","year":"2007","unstructured":"Weniger MA, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer. 2007;46(4):406\u201315.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"5053_CR30","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.leu.2404919","volume":"21","author":"S Wessendorf","year":"2007","unstructured":"Wessendorf S, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia. 2007;21(12):2463\u20139.","journal-title":"Leukemia"},{"issue":"13","key":"5053_CR31","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1073\/pnas.93.13.6721","volume":"93","author":"HY Song","year":"1996","unstructured":"Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1\/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996;93(13):6721\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5053_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1084\/jem.20090528","volume":"206","author":"R Schmitz","year":"2009","unstructured":"Schmitz R, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981\u20139.","journal-title":"J Exp Med"},{"issue":"12","key":"5053_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/gcc.20495","volume":"46","author":"LR Kimm","year":"2007","unstructured":"Kimm LR, et al. Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer. 2007;46(12):1090\u20137.","journal-title":"Genes Chromosomes Cancer"},{"issue":"23","key":"5053_CR34","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","volume":"128","author":"L Mansouri","year":"2016","unstructured":"Mansouri L, et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128(23):2666\u201370.","journal-title":"Blood"},{"issue":"3","key":"5053_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-020-0305-6","volume":"10","author":"V Della-Valle","year":"2020","unstructured":"Della-Valle V, et al. Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. Blood Cancer J. 2020;10(3):38.","journal-title":"Blood Cancer J"},{"issue":"10","key":"5053_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.2019001126","volume":"134","author":"A Mottok","year":"2019","unstructured":"Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134(10):802\u201313.","journal-title":"Blood"},{"issue":"1","key":"5053_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","volume":"11","author":"LT Lam","year":"2005","unstructured":"Lam LT, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11(1):28\u201340.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5053_CR38","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116(9):1515\u201323.","journal-title":"Blood"},{"issue":"3","key":"5053_CR39","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ymthe.2020.11.026","volume":"29","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. Targeted in vivo delivery of NF-\u03baB decoy inhibitor augments sensitivity of B cell lymphoma to therapy. Mol Ther. 2021;29(3):1214\u201325.","journal-title":"Mol Ther"},{"issue":"16","key":"5053_CR40","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","volume":"131","author":"CS Sauter","year":"2018","unstructured":"Sauter CS, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018;131(16):1805\u20138.","journal-title":"Blood"},{"key":"5053_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.biocel.2017.12.020","volume":"95","author":"J Bennett","year":"2018","unstructured":"Bennett J, et al. NF-\u03baB in the crosshairs: Rethinking an old riddle. Int J Biochem Cell Biol. 2018;95:108\u201312.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"5053_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.15778","volume":"185","author":"C Lees","year":"2019","unstructured":"Lees C, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185(1):25\u201341.","journal-title":"Br J Haematol"},{"issue":"4","key":"5053_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/MOH.0000000000000155","volume":"22","author":"A Mottok","year":"2015","unstructured":"Mottok A, Steidl C. Genomic alterations underlying immune privilege in malignant lymphomas. Curr Opin Hematol. 2015;22(4):343\u201354.","journal-title":"Curr Opin Hematol"},{"issue":"7338","key":"5053_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377\u201381.","journal-title":"Nature"},{"issue":"1","key":"5053_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","volume":"108","author":"RA Roberts","year":"2006","unstructured":"Roberts RA, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311\u20138.","journal-title":"Blood"},{"key":"5053_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.cellbio.24.110707.175347","volume":"24","author":"DR Peaper","year":"2008","unstructured":"Peaper DR, Cresswell P. Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol. 2008;24:343\u201368.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"5053_CR47","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, et al. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov. 2019;9(4):546\u201363.","journal-title":"Cancer Discov"},{"issue":"4","key":"5053_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1200\/JCO.23.01053","volume":"42","author":"D Noerenberg","year":"2024","unstructured":"Noerenberg D, et al. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes. J Clin Oncol. 2024;42(4):452\u201366.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5053_CR49","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ccell.2023.05.014","volume":"41","author":"P Ho","year":"2023","unstructured":"Ho P, et al. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell. 2023;41(7):1207\u2013e122112.","journal-title":"Cancer Cell"},{"issue":"3","key":"5053_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/blood.V98.3.533","volume":"98","author":"P Ghia","year":"2001","unstructured":"Ghia P, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001;98(3):533\u201340.","journal-title":"Blood"},{"issue":"2","key":"5053_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","volume":"93","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, et al. Correlation of high numbers of intratumoral FOXP3\u2009+\u2009regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica. 2008;93(2):193\u2013200.","journal-title":"Haematologica"},{"issue":"1","key":"5053_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","volume":"40","author":"W Fang","year":"2021","unstructured":"Fang W, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion. J Exp Clin Cancer Res. 2021;40(1):4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5053_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-023-00396-0","volume":"12","author":"RE Steiner","year":"2023","unstructured":"Steiner RE, et al. PD-L1(+) macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol. 2023;12(1):32.","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"5053_CR54","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"26","key":"5053_CR55","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"34","key":"5053_CR56","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5053_CR57","first-page":"141","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141\u20135.","journal-title":"Blood"},{"issue":"1","key":"5053_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"5053_CR59","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41375-023-02013-9","volume":"37","author":"F Briest","year":"2023","unstructured":"Briest F, et al. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Leukemia. 2023;37(11):2237\u201349.","journal-title":"Leukemia"},{"key":"5053_CR60","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/01.HS9.0000847648.48346.f9","volume":"6","author":"I Kamaeva","year":"2022","unstructured":"Kamaeva I, et al. Different mutations in patients with primary large B-cell lymphoma. HemaSphere. 2022;6:2085.","journal-title":"HemaSphere"},{"issue":"8","key":"5053_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2015-07-653386","volume":"126","author":"M Meignan","year":"2015","unstructured":"Meignan M. Quantitative FDG-PET: a new biomarker in PMBCL. Blood. 2015;126(8):924\u20136.","journal-title":"Blood"},{"issue":"8","key":"5053_CR62","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","volume":"126","author":"L Ceriani","year":"2015","unstructured":"Ceriani L, et al. Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950\u20136.","journal-title":"Blood"},{"issue":"4","key":"5053_CR63","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14728","volume":"178","author":"L Ceriani","year":"2017","unstructured":"Ceriani L, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET\/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178(4):588\u201391.","journal-title":"Br J Haematol"},{"issue":"2","key":"5053_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","volume":"132","author":"L Ceriani","year":"2018","unstructured":"Ceriani L, et al. Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018;132(2):179\u201386.","journal-title":"Blood"},{"key":"5053_CR65","doi-asserted-by":"crossref","unstructured":"Yousefirizi F et al. Evaluating outcome prediction via baseline, end-of-treatment, and delta radiomics on PET-CT images of primary mediastinal large B-cell lymphoma. Cancers (Basel), 2024; 16(6).","DOI":"10.3390\/cancers16061090"},{"issue":"7","key":"5053_CR66","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436\u201347.","journal-title":"Ann Oncol"},{"issue":"17","key":"5053_CR67","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","volume":"32","author":"M Martelli","year":"2014","unstructured":"Martelli M, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32(17):1769\u201375.","journal-title":"J Clin Oncol"},{"issue":"34","key":"5053_CR68","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO-24-01373","volume":"42","author":"M Martelli","year":"2024","unstructured":"Martelli M, et al. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. J Clin Oncol. 2024;42(34):4071\u201383.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5053_CR69","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","volume":"44","author":"J Lazarovici","year":"2017","unstructured":"Lazarovici J, et al. Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017;44(12):2018\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5053_CR70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.09.017","volume":"94","author":"MW Jackson","year":"2016","unstructured":"Jackson MW, et al. Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. Int J Radiat Oncol Biol Phys. 2016;94(1):126\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5053_CR71","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ijrobp.2011.09.012","volume":"83","author":"A Avil\u00e9s","year":"2012","unstructured":"Avil\u00e9s A, et al. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1227\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5053_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/pro6.1070","volume":"3","author":"A Avil\u00e9s","year":"2019","unstructured":"Avil\u00e9s A, et al. Radiotherapy after immunochemotherapy improves outcomes in patients with primary mediastinal large B-cell lymphoma. Precision Radiation Oncol. 2019;3(4):145\u20138.","journal-title":"Precision Radiation Oncol"},{"issue":"11","key":"5053_CR73","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/ajh.24172","volume":"90","author":"S Giri","year":"2015","unstructured":"Giri S, et al. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis. Am J Hematol. 2015;90(11):1052\u20134.","journal-title":"Am J Hematol"},{"issue":"8","key":"5053_CR74","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","volume":"103","author":"C Melani","year":"2018","unstructured":"Melani C, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica. 2018;103(8):1337\u201344.","journal-title":"Haematologica"},{"issue":"5","key":"5053_CR75","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jayao.2019.0018","volume":"8","author":"S Jiang","year":"2019","unstructured":"Jiang S, Zhen H, Jiang H. Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis. J Adolesc Young Adult Oncol. 2019;8(5):623\u20137.","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"7","key":"5053_CR76","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1097\/HS9.0000000000000917","volume":"7","author":"G Held","year":"2023","unstructured":"Held G, et al. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial. Hemasphere. 2023;7(7):e917.","journal-title":"Hemasphere"},{"issue":"5","key":"5053_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739\u201347.","journal-title":"Br J Haematol"},{"issue":"11","key":"5053_CR78","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/bloodadvances.2018017681","volume":"2","author":"CC Pinnix","year":"2018","unstructured":"Pinnix CC, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;2(11):1334\u201343.","journal-title":"Blood Adv"},{"issue":"7","key":"5053_CR79","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jcma.2015.02.005","volume":"78","author":"SH Yang","year":"2015","unstructured":"Yang SH, et al. Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. J Chin Med Assoc. 2015;78(7):400\u20137.","journal-title":"J Chin Med Assoc"},{"issue":"12","key":"5053_CR80","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3324\/haematol.2014.111203","volume":"99","author":"T Aoki","year":"2014","unstructured":"Aoki T, et al. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica. 2014;99(12):1817\u201325.","journal-title":"Haematologica"},{"issue":"5","key":"5053_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","volume":"10","author":"H Zhou","year":"2020","unstructured":"Zhou H, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020;10(5):49.","journal-title":"Blood Cancer J"},{"issue":"2","key":"5053_CR82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/ol.2023.14190","volume":"27","author":"HJ Shih","year":"2024","unstructured":"Shih HJ, et al. Major impact of prognosis by age and sex in patients with primary mediastinal large B\u2013cell lymphoma. Oncol Lett. 2024;27(2):57.","journal-title":"Oncol Lett"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05053-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:03:54Z","timestamp":1783497834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5053"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05053-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1001"}}